Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Current Deferred Revenue (2022 - 2025)

Core Laboratories (CLB) has 3 years of Current Deferred Revenue data on record, last reported at $9.3 million in Q4 2024.

  • For Q4 2024, Current Deferred Revenue rose 96.26% year-over-year to $9.3 million; the TTM value through Dec 2024 reached $9.3 million, up 96.26%, while the annual FY2024 figure was $9.3 million, 96.26% up from the prior year.
  • Current Deferred Revenue reached $9.3 million in Q4 2024 per CLB's latest filing, up from $7.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $9.3 million in Q4 2024 and bottomed at $4.6 million in Q3 2023.
  • Average Current Deferred Revenue over 3 years is $6.2 million, with a median of $5.7 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: dropped 19.98% in 2023, then skyrocketed 96.26% in 2024.
  • A 3-year view of Current Deferred Revenue shows it stood at $5.9 million in 2022, then decreased by 19.98% to $4.8 million in 2023, then surged by 96.26% to $9.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $9.3 million in Q4 2024, $7.2 million in Q3 2024, and $5.5 million in Q2 2024.